Lessons From Tarceva in Pancreatic Cancer: Where Are We Now, and How Should Future Trials Be Designed in Pancreatic Cancer?

Current Opinion in Oncology - United States
doi 10.1097/cco.0b013e32830218d6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Early Detection of Pancreatic Cancer: Where Are We Now and Where Are We Going?

International Journal of Cancer
Cancer ResearchOncology
2017English

Breast Cancer Research: Where We Are and Where We Should Go

Breast Cancer Research
Cancer ResearchOncology
2000English

Incorporating Sex as a Biological Variable in Neuropsychiatric Research: Where Are We Now and Where Should We Be?

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2016English

Governance Indicators: Where Are We, Where Should We Be Going?

World Bank Research Observer
DevelopmentEconomicsEconometrics
2007English

Diversity, Innovation and Entrepreneurship: Where Are We and Where Should We Go in Future Studies?

Small Business Economics
AccountingManagementEconomicsEconometricsBusiness
2019English

Where Are We Now?

Veterinary Record
MedicineVeterinary
2014English

Novel Discoveries Targeting Gemcitabine‐based Chemoresistance and New Therapies in Pancreatic Cancer: How Far Are We From the Destination?

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?

Immunity
Infectious DiseasesAllergyImmunology
2010English

Understanding Diabetic Teratogenesis: Where Are We Now and Where Are We Going?

Birth Defects Research Part A - Clinical and Molecular Teratology
Child HealthPediatricsPerinatologyMedicineDevelopmental BiologyEmbryology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy